<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The 9th European Hematology Association Congress, held in Geneva, Switzerland, from 10 through 13 June 2004, offered a number of educational programmes that focused on <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>This report will summarize the material presented at the educational symposium entitled 'Evolving Trends in the Treatment of Low-Risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>: Immunomodulation and Beyond' </plain></SENT>
<SENT sid="2" pm="."><plain>The overview of the presentations includes a comparative review of the classification systems for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; a discussion of treatment strategies and management issues for patients in lower risk disease categories; a description of a novel class of immunomodulators, the IMiDs((R)), and a presentation of updated data from clinical trials of the IMiD compound, lenalidomide, in the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>